Urinary leukotriene E4 and 11‐dehydrothromboxane B2 in patients with aspirin‐sensitive asthma
暂无分享,去创建一个
H. Mita | K. Akiyama | Y. Mizushima | T. Shida | M. Kobayashi | R. Oosaki
[1] H. Mita,et al. [Fundamental studies on the measurement of urinary leukotriene E4]. , 1994, Arerugi = [Allergy].
[2] E. Israel,et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. , 1993, The American review of respiratory disease.
[3] S. Dahlén,et al. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. , 1992, The American review of respiratory disease.
[4] T. Lee,et al. Urinary leukotriene E4 in bronchial asthma. , 1992, The European respiratory journal.
[5] H. Vapaatalo,et al. Solid-phase extraction of urinary 11-dehydrothromboxane B2 for reliable determination with radioimmunoassay. , 1992, Analytical biochemistry.
[6] T. Lee,et al. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. , 1991, The American review of respiratory disease.
[7] A. Ford-hutchinson,et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. , 1991, The American review of respiratory disease.
[8] N. Voelkel,et al. Leukotriene E4 elimination and metabolism in normal human subjects. , 1990, The Journal of biological chemistry.
[9] M. Kumlin,et al. Identification of 11-dehydro-TXB2 as a suitable parameter for monitoring thromboxane production in the human. , 1986, Prostaglandins.
[10] R. Lewis,et al. Arachidonic acid derivatives as mediators of asthma. , 1985, The Journal of allergy and clinical immunology.
[11] Partridge,et al. International Consensus Report on Diagnosis and Treatment of Asthma. , 1992, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[12] Phillips Yy,et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.